Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

Epidemiology of childhood and adolescent cancer in Bangladesh, 2001–2014

Authors: Mohammad Sorowar Hossain, Mamtaz Begum, Md Mahmuduzzaman Mian, Shameema Ferdous, Shahinur Kabir, Humayun Kabir Sarker, Sabina Karim, Salma Choudhury, Asaduzzaman Khan, Zohora Jameela Khan, Henrike E. Karim-Kos

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Cancer burden among children and adolescents is largely unknown in Bangladesh. This study aims to provide a comprehensive overview on childhood and adolescent cancers and to contribute to the future strategies to deal with these diseases in Bangladesh.

Methods

Data on malignant neoplasms in patients aged less than 20 years diagnosed between 2001 and 2014 (N = 3143) in Bangladesh was collected by the National Institute of Cancer Research and Hospital and ASHIC Foundation. The age pattern and distribution of cancer types were analysed and the incidence rates were calculated.

Results

The age-standardised incidence rate was 7.8 per million person-years for children (0–14 years) in the last time period (2011–2014). Retinoblastoma (25 %) and leukaemia (18 %) were the most common childhood cancers. For adolescents (15–19 years), the age-specific incidence rate was 2.1 per million person-years in the same time period. Most common adolescent cancers were malignant bone tumours (38 %), germ cell and gonadal tumours (17 %), and epithelial tumours (16 %). There were more boys affected (M: F ratio 2.0 in children and 1.4 in adolescents) than girls.

Conclusion

Cancer incidences were lower than expected most likely due to a low level of awareness about cancer among clinicians and the population, inadequate access to health care, lack of diagnostic equipment and incomplete recording of cases. Improvements on different levels should be made to get a better epidemiologic insight and to detect cancer earlier resulting in a better outcome for affected children and adolescents.
Literature
1.
Magrath I, Steliarova-Foucher E, Epelman S, Ribeiro RC, Harif M, Li CK, Kebudi R, Macfarlane SD, Howard SC. Paediatric cancer in low-income and middle-income countries. Lancet Oncol. 2013;14(3):e104–16.
2.
Rodriguez-Galindo C, Friedrich P, Morrissey L, Frazier L. Global challenges in pediatric oncology. Curr Opin Pediatr. 2013;25(1):3–15.CrossRefPubMed
3.
Hossain MS, Ferdous S, Karim-Kos HE. Breast cancer in South Asia: a Bangladeshi perspective. Cancer Epidemiol. 2014;38(5):465–70.CrossRefPubMed
4.
Hossain MS, Iqbal MS, Khan MA, Rabbani MG, Khatun H, Munira S, Miah MM, Kabir AL, Islam N, Dipta TF et al. Diagnosed hematological malignancies in Bangladesh - a retrospective analysis of over 5000 cases from 10 specialized hospitals. BMC Cancer. 2014;14:438.
5.
6.
Arora RS, Eden TO, Kapoor G. Epidemiology of childhood cancer in India. Indian J Cancer. 2009;46(4):264–73.CrossRefPubMed
7.
Howard SC, Metzger ML, Wilimas JA, Quintana Y, Pui CH, Robison LL, Ribeiro RC. Childhood cancer epidemiology in low-income countries. Cancer. 2008;112(3):461–72.
8.
9.
10.
11.
Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International classification of childhood cancer, third edition. Cancer. 2005;103(7):1457–67.CrossRefPubMed
12.
13.
Jabeen S, Haque M, Islam MJ, Talikder MH. Profile of paediatric malignancies: a five year study. J Dhaka Med Coll. 2010;19:33–8.CrossRef
14.
Hasan GZ, Hossain AKMZ, Amin MR, Siddiqui MTH, Islam KMD. Pattern of childhood malignant tumour in the Paediatric Surgery Department of Bangabandhu Sheikh Mujib Medical University. BSMMU J. 2011;4:99–101.
15.
Bhopal SS, Mann KD, Pearce MS. Registration of cancer in girls remains lower than expected in countries with low/middle incomes and low female education rates. Br J Cancer. 2012;107(1):183–8.PubMedCentralCrossRefPubMed
16.
Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83–103.CrossRefPubMed
17.
Dimaras H, Kimani K, Dimba EA, Gronsdahl P, White A, Chan HS, Gallie BL. Retinoblastoma. Lancet. 2012;379(9824):1436–46.
18.
Chantada G, Fandino A, Manzitti J, Urrutia L, Schvartzman E. Late diagnosis of retinoblastoma in a developing country. Arch Dis Child. 1999;80(2):171–4.PubMedCentralCrossRefPubMed
19.
Rodrigues KE, Latorre Mdo R, de Camargo B. Delayed diagnosis in retinoblastoma. J Pediatr (Rio J). 2004;80(6):511–6.CrossRef
20.
Abramson DH, Beaverson K, Sangani P, Vora RA, Lee TC, Hochberg HM, Kirszrot J, Ranjithan M. Screening for retinoblastoma: presenting signs as prognosticators of patient and ocular survival. Pediatrics. 2003;112(6 Pt 1):1248–55.
21.
Leander C, Fu LC, Pena A, Howard SC, Rodriguez-Galindo C, Wilimas JA, Ribeiro RC, Haik B. Impact of an education program on late diagnosis of retinoblastoma in Honduras. Pediatr Blood Cancer. 2007;49(6):817–9.
22.
Badar F, Mahmood S, Zaidi A, Bhurgri Y. Age-standardized incidence rates for childhood cancers at a cancer hospital in a developing country. Asian Pac J Cancer Prev. 2009;10(5):753–8.PubMed
23.
Datta K, Choudhuri M, Guha S, Biswas J. Childhood cancer burden in part of eastern India--Population Based Cancer Registry data for Kolkata (1997–2004). Asian Pac J Cancer Prev. 2011;11(5):1283–8.
24.
Azevedo-Silva F, Reis Rde S, Santos Mde O, Luiz RR, Pombo-de-Oliveira MS. Evaluation of childhood acute leukemia incidence and underreporting in Brazil by capture-recapture methodology. Cancer Epidemiol. 2009;33(6):403–5.CrossRefPubMed
25.
Bajel A, George B, Mathews V, Viswabandya A, Kavitha ML, Srivastava A, Chandy M. Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol. Pediatr Blood Cancer. 2008;51(5):621–5.
26.
Fadoo Z, Nisar I, Yousuf F, Lakhani LS, Ashraf S, Imam U, Zaheer J, Naqvi A, Belgaumi A. Clinical features and induction outcome of childhood acute lymphoblastic leukemia in a lower/middle income population: a multi-institutional report from Pakistan. Pediatr Blood Cancer. 2015;62(10):1700–8.
27.
Sazawal S, Gurbuxani S, Bhatia K, Khattar A, Raina V, Arya LS, Vats T, Magrath I, Bhargava M. Incidence, clinical characteristics and early treatment outcome in Indian patients of childhood acute lymphoblastic leukemia with ALL-1 gene rearrangement. Leuk Res. 2001;25(8):693–8.
28.
McKinney PA, Feltbower RG, Parslow RC, Lewis IJ, Glaser AW, Kinsey SE. Patterns of childhood cancer by ethnic group in Bradford, UK 1974–1997. Eur J Cancer. 2003;39(1):92–7.CrossRefPubMed
29.
Baade PD, Youlden DR, Valery PC, Hassall T, Ward L, Green AC, Aitken JF. Trends in incidence of childhood cancer in Australia, 1983–2006. Br J Cancer. 2007;102(3):620–6.
30.
Hung GY, Horng JL, Lee YS, Yen HJ, Chen CC, Lee CY. Cancer incidence patterns among children and adolescents in Taiwan from 1995 to 2009: a population-based study. Cancer. 2014;120(22):3545–53.PubMedCentralCrossRefPubMed
31.
Kaatsch P, Steliarova-Foucher E, Crocetti E, Magnani C, Spix C, Zambon P. Time trends of cancer incidence in European children (1978–1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42(13):1961–71.CrossRefPubMed
32.
Clavel J, Steliarova-Foucher E, Berger C, Danon S, Valerianova Z. Hodgkin’s disease incidence and survival in European children and adolescents (1978–1997): report from the Automated Cancer Information System project. Eur J Cancer. 2006;42(13):2037–49.CrossRefPubMed
Metadata
Title
Epidemiology of childhood and adolescent cancer in Bangladesh, 2001–2014
Authors
Mohammad Sorowar Hossain
Mamtaz Begum
Md Mahmuduzzaman Mian
Shameema Ferdous
Shahinur Kabir
Humayun Kabir Sarker
Sabina Karim
Salma Choudhury
Asaduzzaman Khan
Zohora Jameela Khan
Henrike E. Karim-Kos
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2161-0

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Research article

Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study

Research article

Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer

Research article

An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma

Research article

Impact of the introduction of EBUS on time to management decision, complications, and invasive modalities used to diagnose and stage lung cancer: a pragmatic pre-post study

Research article

Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib

Debate

Chemotherapy curable malignancies and cancer stem cells: a biological review and hypothesis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits